Abstract
The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 354-364 |
| Number of pages | 11 |
| Journal | Drug Discovery Today |
| Volume | 15 |
| Issue number | 9-10 |
| DOIs | |
| State | Published - May 2010 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
Cite this
New promising drug targets in cancer- and mtastasis-initiating cells. / Mimeault, Murielle; Batra, Surinder Kumar.
In: Drug Discovery Today, Vol. 15, No. 9-10, 05.2010, p. 354-364.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - New promising drug targets in cancer- and mtastasis-initiating cells
AU - Mimeault, Murielle
AU - Batra, Surinder Kumar
PY - 2010/5
Y1 - 2010/5
N2 - The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.
AB - The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.
UR - http://www.scopus.com/inward/record.url?scp=77950853025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950853025&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2010.03.009
DO - 10.1016/j.drudis.2010.03.009
M3 - Review article
C2 - 20338259
AN - SCOPUS:77950853025
VL - 15
SP - 354
EP - 364
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 9-10
ER -